Skip to main content
Premium Trial:

Request an Annual Quote

Ariad Patents Technology for Regulating Gene Expression

NEW YORK, Feb 13 – Ariad Pharmaceuticals received a patent for a method to control gene expression in humans and other animals, the company said Tuesday.

The technology uses small molecules to regulate the extent of gene activation. It is part of Ariad’s Argent gene regulation system, a gene regulation technology designed for high throughput analysis of in vitro and in vivo gene function, and " dose-dependent control” of gene and cell therapy products, Ariad said.

Ariad of Cambridge, Mass., which has developed several drug candidates based on its cellular regulation technology, is making newly-patented method and accompanying technology available for license, CEO Harvey Berger said in a statement.

Ariad said it has previously licensed its other gene regulation technologies to hundreds of academic institutions.

The Scan

Review of Approval Process

Stat News reports the Department for Health and Human Services' Office of the Inspector General is to investigate FDA's approval of Biogen's Alzheimer's disease drug.

Not Quite Right

A new analysis has found hundreds of studies with incorrect nucleotide sequences reported in their methods, according to Nature News.

CRISPR and mRNA Together

Time magazine reports on the use of mRNA to deliver CRISPR machinery.

Nature Papers Present Smartphone Platform for DNA Diagnosis of Malaria, Mouse Lines for Epigenomic Editing

In Nature this week: a low-cost tool to detect infectious diseases like malaria, and more.